

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

<i>Complete if Known</i>	
Application Number	10/597,304
Filing Date	July 19, 2006
First Named Inventor	John P. Morseman
Art Unit	1628
Examiner Name	Jennifer M. Kim
Sheet	1 of 1
Attorney Docket Number	2997-74-PUS

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	-----------------------	---	--------------------------------	--	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
--------------------	-----------------------	---	--------------------------------	--	--	----------------

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	Other Art
	1	COSTA, E. et al., "Dendritic spine hypoplasia and downregulation of reelin and GABAergic tone in schizophrenia vulnerability," Neurobiology of Disease, Blackwell Scientific Publications, Oxford, GB, Vol. 8, No. 5, Oct. 1, 2001, pp. 723-742
	2	PEET MALCOLM, "Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical trial results," Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 69, No. 6, Dec. 2003, pp. 477-485

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.